News

The acquisition bolsters AscellaHealth’s capabilities to serve international manufacturers and patients in more than 70 countries across the EU, Asia, Africa, Australia and the Americas. CHAPPER healthcare is

This designation is a significant milestone for the monoclonal antibody plasma kallikrein inhibitor, which is designed to provide long-acting prevention of HAE attacks. Navenibart is effective even without

This partnership will see RTI, alongside investors such as Genoa Ventures and Anzu Partners, investing in Codetta Bio. RTI will also integrate Codetta Bio’s technology into research initiatives.

The platform can detect unintended pH changes, bolster formulation stability, and lower viscosity for ensuring efficacy and maximising delivery of drugs. S-HiCon incorporates a preliminary ‘concentration gate check’

The CRDAC’s positive vote is a pivotal step towards the potential approval of elamipretide, a first-in-class mitochondria-targeted therapy. The committee concluded with a 10 to 6 vote that

The drug is under evaluation in Phase IIb studies for both primary sclerosing cholangitis under the VISTAS study and PBC under the VANTAGE study. This milestone is based on the

This collaboration will focus on developing new medicines for conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), utilising targets identified by insitro’s AI/ML-based platform. The new partnership

The contract, with a maximum value of $80m over a five-year period, is part of the NIH’s Helping to End Addiction Long-term Initiative (HEAL Initiative) and falls under

On receipt of approval, this asset could become the first disease-modifying therapy for ALS, focusing on immunologic mechanisms rather than neurologic. A sodium chlorite infusion, NP001 has been